Slides on the current situation with global cigarette consumption and trends, and how new nicotine products could change things.
See blog at: http://www.clivebates.com/?p=2782 for more commentary.
What is wrong (and right) about the Tobacco Products Directive approach to E-...Clive Bates
These are the visual aids for my talk on the truly dreadful European Union Tobacco Products Directive as it applies to e-cigarettes, and why Totally Wicked has a legal case against it.
FDLI - Lesson for the US from other jurisdictions - the United Kingdom -29 Oc...Clive Bates
Presentation on the most significant differences between US and UK/EU regulation of tobacco and vaping products. FDLI Tobacco and Nicotine Products Regulation and Policy Conference
Nicotina - Reducción de riesgos y daños / Nicotine - Risk and Harm ReductionClive Bates
Presentación en línea para el seminario de políticas en Colombia enfocado en políticas de vapeo y consecuencias no deseadas /
Presentation online for policy seminar in Colombia focussed on vaping policy and unintended consequences
India - Economic Times - Consumer Freedom Conclave - 24 Feb 2022Clive Bates
Tobacco harm reduction: the biggest public health win of the 21st Century?
1. Tobacco harm reduction
2. Risk communication
3. Policymaking
4. Cause of opposition
5. Innovation
What is wrong (and right) about the Tobacco Products Directive approach to E-...Clive Bates
These are the visual aids for my talk on the truly dreadful European Union Tobacco Products Directive as it applies to e-cigarettes, and why Totally Wicked has a legal case against it.
FDLI - Lesson for the US from other jurisdictions - the United Kingdom -29 Oc...Clive Bates
Presentation on the most significant differences between US and UK/EU regulation of tobacco and vaping products. FDLI Tobacco and Nicotine Products Regulation and Policy Conference
Nicotina - Reducción de riesgos y daños / Nicotine - Risk and Harm ReductionClive Bates
Presentación en línea para el seminario de políticas en Colombia enfocado en políticas de vapeo y consecuencias no deseadas /
Presentation online for policy seminar in Colombia focussed on vaping policy and unintended consequences
India - Economic Times - Consumer Freedom Conclave - 24 Feb 2022Clive Bates
Tobacco harm reduction: the biggest public health win of the 21st Century?
1. Tobacco harm reduction
2. Risk communication
3. Policymaking
4. Cause of opposition
5. Innovation
E-cigarette Summit - The New Tobacco Wars - 7 December 2021Clive Bates
The presentation gives my take on the conflict raging in tobacco control. It looks at where things are going wrong in science, risk communication, policy, and youth politics. It then looks at causes: institutional and cultural inertia. And finally, finds hope in the basic processes of innovation.
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
Albania National Association of Public health - Harm Reduction ConferenceClive Bates
Seven insights into tobacco harm reduction (20 min version) 20th December 2021.
1.The problem is smoking
2. Smoke-free alternatives
3. Quitting smoking with smoke-free alternatives
4. Health concerns
5. Youth vaping
6. Policy and unintended consequences
7. Innovation (and its enemies)
Seven insights into tobacco harm reductionClive Bates
1st Tobacco Harm Reduction Malaysia Scientific Meeting
21 November 2021.
1. The problem is smoking
2. Smoke-free alternatives
3. Quitting smoking with smoke-free alternatives
4. Health concerns
5. Youth vaping
6. Policy and unintended consequences
7. Innovation (and its enemies)
This presentation was developed for our CLeaR (local government tobacco control standards) assessment in July 2014. It sets out our vision for tobacco control in Hertfordshire, summarises our strategies and current position and identifies our future work including commitment to harm reduction, getting positive gains from e-cigarettes and driving tobacco related harm down
Regulation: why less is more... E-cigarette Summit 12 November 2013 - Clive B...Clive Bates
My presentation covering why 'less is more' when it comes to regulating low risk alternatives to cigarettes such as e-cigarettes. Too much regulation will limit appeal, increase costs, raise barriers to entry and inhibit innovation. I also urge a focus on the huge potential benefits of low-risk alternatives to smoking instead of obsession over minor or implausible risks.
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...Clive Bates
Clive Bates presentation at a seminar in the European Parliament organised by Monika Beňová MEP
European Commission DG SANTE - Matus Ferech
Patient Access Partnership - Dr. Stanimir Hasurdjiev
Vaping and tobacco: six things you need to know about harm reductionClive Bates
1. Smoking has not gone away
2. Technologies to obsolete cigarettes
3. Risks and risk (mis)perceptions
4. The public health mechanism and the pleasure principle
5. The youth vaping epidemic – a harder look
6. Policymaking and perverse consequences
NYU College of Global Health - E-cigarette seminar - New YorkClive Bates
E-Cigarettes: The Tectonic Shift in Nicotine and Tobacco Consumption: Opportunity or Threat to Saving Lives?
Clive Bates
Friday, October 19, 2018
NYU School of Law, Greenberg Lounge
40 Washington Square South, New York, New York
Effects of alternative nicotine delivery systems on cigarette consumption and...Clive Bates
Presentation at SRNT-Europe Conference September 2019 on the impact of vaping and other reduced-risk products on cigarette sales and smoking prevalence.
To see the fully animated version, please download.
The MRTP process - Seven provocations - FDLI webinar 30 July 2020Clive Bates
My presentation for a Food and Drug Law Institute webinar on the FDA's Modified Risk Tobacco Product process for making risk-related claims about tobacco and nicotine products
E-cigarette Summit - The New Tobacco Wars - 7 December 2021Clive Bates
The presentation gives my take on the conflict raging in tobacco control. It looks at where things are going wrong in science, risk communication, policy, and youth politics. It then looks at causes: institutional and cultural inertia. And finally, finds hope in the basic processes of innovation.
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
Albania National Association of Public health - Harm Reduction ConferenceClive Bates
Seven insights into tobacco harm reduction (20 min version) 20th December 2021.
1.The problem is smoking
2. Smoke-free alternatives
3. Quitting smoking with smoke-free alternatives
4. Health concerns
5. Youth vaping
6. Policy and unintended consequences
7. Innovation (and its enemies)
Seven insights into tobacco harm reductionClive Bates
1st Tobacco Harm Reduction Malaysia Scientific Meeting
21 November 2021.
1. The problem is smoking
2. Smoke-free alternatives
3. Quitting smoking with smoke-free alternatives
4. Health concerns
5. Youth vaping
6. Policy and unintended consequences
7. Innovation (and its enemies)
This presentation was developed for our CLeaR (local government tobacco control standards) assessment in July 2014. It sets out our vision for tobacco control in Hertfordshire, summarises our strategies and current position and identifies our future work including commitment to harm reduction, getting positive gains from e-cigarettes and driving tobacco related harm down
Regulation: why less is more... E-cigarette Summit 12 November 2013 - Clive B...Clive Bates
My presentation covering why 'less is more' when it comes to regulating low risk alternatives to cigarettes such as e-cigarettes. Too much regulation will limit appeal, increase costs, raise barriers to entry and inhibit innovation. I also urge a focus on the huge potential benefits of low-risk alternatives to smoking instead of obsession over minor or implausible risks.
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...Clive Bates
Clive Bates presentation at a seminar in the European Parliament organised by Monika Beňová MEP
European Commission DG SANTE - Matus Ferech
Patient Access Partnership - Dr. Stanimir Hasurdjiev
Vaping and tobacco: six things you need to know about harm reductionClive Bates
1. Smoking has not gone away
2. Technologies to obsolete cigarettes
3. Risks and risk (mis)perceptions
4. The public health mechanism and the pleasure principle
5. The youth vaping epidemic – a harder look
6. Policymaking and perverse consequences
NYU College of Global Health - E-cigarette seminar - New YorkClive Bates
E-Cigarettes: The Tectonic Shift in Nicotine and Tobacco Consumption: Opportunity or Threat to Saving Lives?
Clive Bates
Friday, October 19, 2018
NYU School of Law, Greenberg Lounge
40 Washington Square South, New York, New York
Effects of alternative nicotine delivery systems on cigarette consumption and...Clive Bates
Presentation at SRNT-Europe Conference September 2019 on the impact of vaping and other reduced-risk products on cigarette sales and smoking prevalence.
To see the fully animated version, please download.
The MRTP process - Seven provocations - FDLI webinar 30 July 2020Clive Bates
My presentation for a Food and Drug Law Institute webinar on the FDA's Modified Risk Tobacco Product process for making risk-related claims about tobacco and nicotine products
Individual Strategic AnalysisSwedish Match, ABTable of Conte.docxannettsparrow
Individual Strategic Analysis
Swedish Match, AB
Table of Contents
I. Introduction
2
Business Case
2
Problem Statement
2
Mission Statement
2
Vision Statement
3
II. External Assessment
3
General Environment
3
Economic
3
Demographic
3
Political/Legal
3-4
Socio-cultural
4
Technological
5
Global
5
III. Competitive Environment
5
Industry Analysis
5
Economic Structure
5
Life Cycle Stage
6
Porter 5 Forces Model
6-7
Industry Attractiveness
7
Strategic Group Analysis
8
Key Success Factors
8-9
Competitor Analysis Model
9-10
IV. Internal Assessment
10
Nature of the Firm
10
Culture & Leadership
10-11
Organizational Structure
12-13
Value Chain Analysis
13-14
Core Competence
14
Financial Ratio Analysis
14-15
V. Strategic Choice
16
SWOT Analysis
16-17
General Strategic Orientation
17
Grand Strategy Clusters
17-18
Grand Strategy Selection Matrix18
BCG Matrix
19
VI. Recommendations
19
Corporate Level Strategy
19
Business Level Strategy
19
VII. Managerial Implications
19-20
VIII. References
20-21
Swedish Match, AB
I. Introduction
Business Case
Swedish Match is headquartered in Stockholm, Sweden and is traded on the Nasdaq Stock Exchange under the ticker symbol SWMAY. Swedish Match manufactures and markets smokeless tobacco, cigars, and pipe tobacco. It is also the world's largest producer of matches and the number three makers of disposable lighters under the brand name Cricket.
Swedish Match has 14,343 employees and manufactures its products in 26 plants and 15 countries and sells its products in 140 countries.
As one can see Swedish Match is a well-diversified company with revenues generated from many product areas.
Swedish Match is the only global producer of snuff and holds a leading position in the Nordic snuff market and in South Africa.
In the U.S., Swedish Match competes against United Smokeless Tobacco, Conwood Inc., Swisher International and National Tobacco Company, LP. In the United States, Swedish Match faces fierce rivalry in the chewing tobacco, snuff, and loose-leaf segments within the smokeless tobacco industry. Within the United States, Swedish Match has the largest market share in the rapidly expanding value-priced segment. In 2001, Swedish Match had over $1.78 billion in sales spread across its various product lines.
History
The origins of Swedish Match and disposable lighter operations can be traced back to Svenska Tandsticks AB, which was founded in 1917. After a consolidation period from 1917-1932, two large companies replaced the twenty independent match manufacturing plants creating Svenska Tandsticks Aktiebolag with Ivar Kreuger as the President. The match company later changed its name to Svenska Tobaks AB (SWA). In 1984 after being transferred to the Swedish holding company Statsforetag AB, SWA was renamed Procordia AB in 1984. In 1985, Procordia acquired Pinkerton Tobacco Company, the leading manufacturer of chewing tobacco in the United States. Volvo acquired 40% of the sh.
24 04-2020 Bds third year lecture on smoking and periodontiumDr. Mamta Singh
Periodontitis is a group of inflammatory diseases affecting the supporting tissues of the tooth (periodontium). The periodontium consists of four tissues : gingiva, alveolar bone and periodontal ligaments. Tobbaco use is one of the modifiable risk factors and has enormous influance on the development, progres and tretmen results of periodontal disease. The relationship between smoking and periodontal health was investigated as early as the miiddle of last century. Smoking is an independent risk factor for the initiation, extent and severity of periodontal disease. Additionally, smoking can lower the chances for successful tretment. Tretmans in patients with periodontal disease must be focused on understanding the relationship between genetic and environmental factors. Only with individual approach we can identify our pacients risks and achieve better results.
FDLI Annual 2024: seven reasons why the litigation will never stopClive Bates
I give seven reaons underpinning the conflicts between FDA and vape companies...
1. Evidential burdens
2. Opaque success criteria
3. Defining APPH
4. Naivety about youth
5. De facto standard setting
6. Assessing products in isolation
7. Poor market surveillance
US E-cigarette Summit: Taming the nicotine industrial complexClive Bates
I look back to 1997 and simpler time in tobacco control, then look at changes in trade, communications, technology and conclude the market is becoming ungovernable
The end of what? UK E-cigarette Summit 2023Clive Bates
The extended version of my presentation to the UK E-cigarette summit 16 November 2023. We look at the following:
1. End of harm or end of nicotine
2. The demand for nicotine
3. The future market for nicotine
4. False risk perceptions
5. Who is to blame
The APPH Standard: What Does it Actually Mean?Clive Bates
My presentation at the Food & Drug Law Institute Tobacco and Nicotine conference 26 October 2023. I discuss five problems with the APPH concept:
1. No means of trading off different types of benefits and detriments
2. Ignores vaping benefits to youth
3. Blind to harmful unintended consequences of marketing denial orders
4. Impossible to estimate population effects at the product level - the standard only makes sense at the category level.
5. The aggregate effect of thousands of single product PMTA determinations may create adverse effects not captured in any individual application (de fact flavour ban)
I finish with three broad proposals:
1. Assess individual risk and marketing strategy pre-market
2. Assess population effects when it is actually possible to observe them - post-market
3. Conduct a single comprehensive market assessment covering all products, including illicit trade
Rethinking nicotine: illusions, delusions and some conclusionsClive Bates
presentation to the UK E-cigarette Summit on 9 December 2022. Looks at how our approach to nicotine must evolve from a "tobacco harm reduction" to treating nicotine like a socially acceptable recreational stimulant with minimal harm.
African Harm Reduction Exchange - Dec 2022Clive Bates
The science behind Tobacco Harm Reduction …and how it impacts policy development and regulation
1. Smoking is the main problem
2. Smokefree products and science
3. Policy and unintended consequences
4. Innovation (and its enemies)
Barriers and unintended consequences How poor regulation of low-risk alternat...Clive Bates
A shirt presentation to Georgian health experts on the dangers of excessive regulation of safer alternatives to smoking causing perverse unintended consequences.
10 provocations on why FDA's regulation of tobacco and nicotine is failing the American public. My presentation to the US E-cigarette Summit 2022 in Washington DC, with bonus content of additional background slides added in.
Regulation of Tobacco Harm Reduction - GFN 2018 ScholarsClive Bates
Global Forum on Nicotine 2018 Scholars meeting on regulation discusses optimum regulation using 4 Ps of marketing framework to consider risk-proportionate regulation
E-cigarette Summit US presentation 2018Clive Bates
My presentation at the E-cigarette Summit Washington DC, 30 April 2018. "The urge to ban: 10 questions to ask first" calling for calm over flavors and the latest moral panic over JUUL.
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
This session provides a comprehensive overview of the latest updates to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (commonly known as the Uniform Guidance) outlined in the 2 CFR 200.
With a focus on the 2024 revisions issued by the Office of Management and Budget (OMB), participants will gain insight into the key changes affecting federal grant recipients. The session will delve into critical regulatory updates, providing attendees with the knowledge and tools necessary to navigate and comply with the evolving landscape of federal grant management.
Learning Objectives:
- Understand the rationale behind the 2024 updates to the Uniform Guidance outlined in 2 CFR 200, and their implications for federal grant recipients.
- Identify the key changes and revisions introduced by the Office of Management and Budget (OMB) in the 2024 edition of 2 CFR 200.
- Gain proficiency in applying the updated regulations to ensure compliance with federal grant requirements and avoid potential audit findings.
- Develop strategies for effectively implementing the new guidelines within the grant management processes of their respective organizations, fostering efficiency and accountability in federal grant administration.
Donate to charity during this holiday seasonSERUDS INDIA
For people who have money and are philanthropic, there are infinite opportunities to gift a needy person or child a Merry Christmas. Even if you are living on a shoestring budget, you will be surprised at how much you can do.
Donate Us
https://serudsindia.org/how-to-donate-to-charity-during-this-holiday-season/
#charityforchildren, #donateforchildren, #donateclothesforchildren, #donatebooksforchildren, #donatetoysforchildren, #sponsorforchildren, #sponsorclothesforchildren, #sponsorbooksforchildren, #sponsortoysforchildren, #seruds, #kurnool
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
ZGB - The Role of Generative AI in Government transformation.pdfSaeed Al Dhaheri
This keynote was presented during the the 7th edition of the UAE Hackathon 2024. It highlights the role of AI and Generative AI in addressing government transformation to achieve zero government bureaucracy
Monitoring Health for the SDGs - Global Health Statistics 2024 - WHOChristina Parmionova
The 2024 World Health Statistics edition reviews more than 50 health-related indicators from the Sustainable Development Goals and WHO’s Thirteenth General Programme of Work. It also highlights the findings from the Global health estimates 2021, notably the impact of the COVID-19 pandemic on life expectancy and healthy life expectancy.
Preliminary findings _OECD field visits to ten regions in the TSI EU mining r...OECDregions
Preliminary findings from OECD field visits for the project: Enhancing EU Mining Regional Ecosystems to Support the Green Transition and Secure Mineral Raw Materials Supply.
Presentation by Jared Jageler, David Adler, Noelia Duchovny, and Evan Herrnstadt, analysts in CBO’s Microeconomic Studies and Health Analysis Divisions, at the Association of Environmental and Resource Economists Summer Conference.
Effects of Extreme Temperatures From Climate Change on the Medicare Populatio...
Are we in the endgame for smoking?
1. Are we in the endgame for smoking?
Clive Bates
Counterfactual
www.clivebates.com
2. Global cigarette consumption - still rising
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
1980 1985 1990 1995 2000 2005 2010
Billionpieces
Global cigarette consumption 1980-2012
Developing countries
Developed countries
3. Number of smokers - still rising
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
-
200
400
600
800
1,000
1,200
1980 1985 1990 1995 2000 2005 2010
Millionadults
Global adult daily smokers - 1980-2012
Males
Females
4. Global cigarette consumption – linear trend
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
y = 53.203x + 2741.8
R² = 0.9669
y = -16.501x + 2437.1
R² = 0.949
y = 36.702x + 5179
R² = 0.8909
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030
Billionpieces
Global cigarette consumption and trends - linear
5. A 2030 ‘endgame’ requires implausible declines
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030
Billionpieces
Global cigarette consumption - phase out by 2030
Global
Developed countries
Developing countries
6. Consumption rising since 2005 but slower
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
y = 44.274x + 4035.9
y = -23.881x + 2022.7
y = 20.393x + 6058.6
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
2005 2010 2015 2020 2025 2030
Billionpieces
Global cigarette consumption and trends since 2005 - linear
Global
Developed countries
Developing countries
7. Recent increase in growth of cigarette consumption
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
-60
-40
-20
-
20
40
60
80
100
120
1980 1985 1990 1995 2000 2005 2010
Billionpieces
Annual change in global cigarette consumption
Global
Developed countries
Developing countries
8. Global cigarette consumption – trend to 2030
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
y = -1.0886x2 + 90.215x + 2525.9
R² = 0.9962
y = -0.3737x2 - 3.7956x + 2363
R² = 0.9843
y = -1.4623x2 + 86.419x + 4888.9
R² = 0.9932
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030
Billionpieces
Global cigarette consumption and trends – parabolic trend
Global
Developed countries
Developing countries
9. Global cigarette consumption – trend to 2050
Data source: Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA
2014; 311: 183–92.
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
1980 1990 2000 2010 2020 2030 2040 2050
Billionpieces
Global cigarette consumption and trends – parabolic trend
Global
Developed countries
Developing countries
10. Cigarette global consumption trend projection to 2030
Consumption 2010-2030 on parabolic trend projection from 1908-2012 data from Ng M, Freeman MK, Fleming TD, et al. Smoking
prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014; 311: 183–92.
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
2010 2015 2020 2025 2030
Billionpieces
Global cigarette consumption 2010-2030 - on trend
Global cigarette
consumption
11. Hypothetical introduction of new nicotine products
Consumption 2010-2030 on parabolic trend projection from 1908-2012 data from Ng M, Freeman MK, Fleming TD, et al. Smoking
prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014; 311: 183–92.
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
2010 2015 2020 2025 2030
Billionpieces
New non-combustible nicotine with high initial but declining growth
Low risk nicotine
consumption
Global cigarette
consumption
12. Hypothetical introduction of new nicotine products
Consumption 2010-2030 on parabolic trend projection from 1908-2012 data from Ng M, Freeman MK, Fleming TD, et al. Smoking
prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014; 311: 183–92.
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
2010 2015 2020 2025 2030
Billionpieces
New non-combustible nicotine with high initial but declining growth
This boundary is harder
to move. It means
reducing both smoking
and nicotine use, and
may require coercive
measures
This boundary is easier to
move. It does not require
limiting or prohibiting
nicotine use and works
through user choice.
Editor's Notes
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
On a linear basis over 30 years
Developed –16 billion per year
Developing +53 billion per year
Global +36 billion per year
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
On a linear basis over 30 years
Developed –16 billion per year
Developing +53 billion per year
Global +37 billion per year
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
On a linear basis over 30 years
Developed –16 billion per year
Developing +53 billion per year
Global +37 billion per year
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
On a linear basis since 2005 - FCTC
Developed –24 billion per year
Developing +44 billion per year
Global +20 billion per year
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000
Source of data: http://jama.jamanetwork.com/article.aspx?articleid=1812960
Supplementary data: http://jama.jamanetwork.com/data/Journals/JAMA/929635/JOI130117supp1_prod.pdf?v=635489893529930000